ONCOLYTIC HERPES SIMPLEX VIRUSES TYPE 1 FOR TREATING BRAIN TUMOURS Russian patent published in 2024 - IPC C12N7/01 C12N15/869 A61K48/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology and virology. Disclosed is the use of oncolytic herpes simplex virus type 1 (oHSV-1) in the manufacture of a drug for treating a brain tumour, wherein said oHSV-1 contains a modified gene, wherein said modification includes: a) gene copy change γ34.5, which is in the genome terminal repeat, making this gene copy γ34.5 unable to express functional protein ICP34.5, and b) deletion of the region of the internal inverted repetition of the genome, leading to the deletion of one copy of each of the genes presented in the two copies and one copy of the duplicated non-coding sequences in the region of the internal inverted repeat, where said genes presented in two copies include genes coding ICP0, ICP4, ICP34.5, ORF P and ORF O, and where all genes presented in one copy in both components of the genome U_L and U_S are intact, so that they are able to express the corresponding functional proteins.

EFFECT: said oncolytic virus HSV-1 has shown excellent anti-tumour activity specific for brain tumours.

21 cl, 3 tbl, 1 ex